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Abstract
Background: Daily step counts is an intuitive metric that has demonstrated success in motivating physical activity
in adults and may hold potential for future public health physical activity recommendations. This review seeks to
clarify the pattern of the associations between daily steps and subsequent all-cause mortality, cardiovascular disease
(CVD) morbidity and mortality, and dysglycemia, as well as the number of daily steps needed for health outcomes.
Methods: A systematic review was conducted to identify prospective studies assessing daily step count measured
by pedometer or accelerometer and their associations with all-cause mortality, CVD morbidity or mortality, and
dysglycemia (dysglycemia or diabetes incidence, insulin sensitivity, fasting glucose, HbA1c). The search was
performed across the Medline, Embase, CINAHL, and the Cochrane Library databases from inception to August 1,
2019. Eligibility criteria included longitudinal design with health outcomes assessed at baseline and subsequent
timepoints; defining steps per day as the exposure; reporting all-cause mortality, CVD morbidity or mortality, and/or
dysglycemia outcomes; adults ≥18 years old; and non-patient populations.
Results: Seventeen prospective studies involving over 30,000 adults were identified. Five studies reported on all-
cause mortality (follow-up time 4–10 years), four on cardiovascular risk or events (6 months to 6 years), and eight on
dysglycemia outcomes (3 months to 5 years). For each 1000 daily step count increase at baseline, risk reductions in
all-cause mortality (6–36%) and CVD (5–21%) at follow-up were estimated across a subsample of included studies.
There was no evidence of significant interaction by age, sex, health conditions or behaviors (e.g., alcohol use,
smoking status, diet) among studies that tested for interactions. Studies examining dysglycemia outcomes report
inconsistent findings, partially due to heterogeneity across studies of glycemia-related biomarker outcomes, analytic
approaches, and sample characteristics.
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Conclusions: Evidence from longitudinal data consistently demonstrated that walking an additional 1000 steps per
day can help lower the risk of all-cause mortality, and CVD morbidity and mortality in adults, and that health
benefits are present below 10,000 steps per day. However, the shape of the dose-response relation is not yet clear.
Data are currently lacking to identify a specific minimum threshold of daily step counts needed to obtain overall
health benefit.
Keywords: Physical activity, Walking, Diabetes, Prevention, Accelerometer, Physical activity guidelines, Public health
Background
The health benefits of physical activity for people of all
ages, fitness levels, and sociodemographic backgrounds
are well-documented [1–4]. Walking is a central compo-
nent of physical activity and public health promotion ef-
forts [1, 5], and daily step counts have demonstrated
success as a target for achieving recommended amounts
of physical activity in adults [6–8]. In addition, the ex-
pansion of wearable activity monitors and smartphones
with activity-tracking capabilities onto the commercial
market over the last 15 years has brought the “steps per
day” activity metric into homes and healthcare systems
across the world [9–11]. The increasing presence and
use of self-monitoring devices and the accessibility of
daily step counts as a physical activity target among the
general population make it an important adjunct to
current public health guidelines [7].
Despite these emerging benefits of steps for public
health, recently-released guidelines for physical activity
concluded there was insufficient evidence to recommend
the number of daily steps needed for health. The associ-
ations of daily step counts with subsequent mortality,
cardiovascular disease (CVD) risk, and type 2 diabetes
were examined as part of the 2018 Physical Activity
Guidelines Advisory Committee Report [6, 7]. This re-
view was limited, however, by the small number of stud-
ies available. The authors identified 11 total articles for
review, of which only 7 were longitudinal design [6, 7].
This area of study is rapidly evolving, and a number of
longitudinal studies (many with large sample sizes) have
since been published. To inform future public health
guidelines for physical activity, it will be important to
summarize the evidence for the prospective relationship
between device-measured daily step counts and health
outcomes. The present review extends the previous ana-
lysis and provides an updated description of the associ-
ation between daily step counts and subsequent CVD
morbidity or mortality, dysglycemia, and all-cause mor-
tality in adults and the patterns of these associations.
We also investigate if these associations vary by age, sex,
or moderating variables (e.g., weight status, alcohol use).
The findings from this review will help form the evi-




A systematic literature search was conducted in Medline,
Embase, CINAHL, and the Cochrane Library from in-
ception to August 1, 2019. The search strategy combined
terms related to daily step count measured by pedometer
or accelerometer with terms related to mortality, CVD,
and dysglycemia (including type 2 diabetes and bio-
markers such as insulin, blood glucose, HOMA, and
HbA1c). A search filter limited results to randomized
controlled trials and cohort studies. Articles addressing
congenital heart disease were excluded.
The same strategy was used to search Medline and
Embase on the OVID platform and adapted for CINAHL
and Cochrane search engines. The search terms used for
each database are provided in Supplemental materials.
Additional citations were identified by expert consult-
ation and review of secondary sources. The systematic
review search strategy was registered with PROSPERO
(CRD42020142656).
Study selection
To be included in the review, studies had to (1) use a
device-based measure of daily step counts; (2) report on
the association between daily step counts and mortality,
CVD incidence (coronary heart disease/ischemic heart
disease, coronary artery disease, stroke, heart failure,
and/or metabolic syndrome), or type 2 diabetes (inci-
dence of type 2 diabetes, dysglycemia, or changes in
measures of insulin, blood glucose, HOMA, and/or
HbA1c) in a prospective design; (3) be written in
English; and (4) include only adults (≥18 years of age).
Studies conducted in diseased populations (e.g., heart
failure, hospitalized patients, hepatitis, end-stage renal
disease) were not included in this review. Study selection
was performed independently by two researchers (KH
and EH), and differences relating to inclusion and exclu-
sion criteria were resolved by consensus of the authors.
Titles and abstracts of 2144 citations were independ-
ently reviewed against inclusion criteria by EH and KH.
Authors excluded 1954 articles at this stage. Review of the
study methods of the remaining 190 articles resulted in
further exclusions. The full text of 42 articles deemed po-
tentially relevant were retrieved for further independent
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review. Among those, 25 were excluded, leaving 17 studies
included in the analysis. The accompanying chart (Fig. 1)
details the results of the screening process.
Data extraction
Two authors (KH and EH) extracted data from the 17 in-
cluded studies into a preformatted table adapted for this
review [12]. Descriptive information included primary
outcomes; covariates included in the statistical models;
sample size; characteristics of study participants — includ-
ing age, sex, and other clinical characteristics; activity
levels of the sample at baseline; exposure measurement —
including duration of monitoring period, type of device,
and number of valid days required for inclusion (acceler-
ometer studies only); statistical methods used; outcome
follow-up time; and authors and year of publication. The
rationale for this study was to describe and discuss the
patterns of the associations between daily step counts and
health outcomes, and as such, data are synthesized and
presented narratively. To aid interpretation and compari-
son across studies, reporting of the exposure of daily step
counts was standardized to 1000 steps per day difference
at the baseline assessment for each health outcome. We
chose the 1000 step per day increment because it required
limited data manipulation to achieve harmonization across
studies, as 7 out of 10 of the harmonized studies reported
1000 steps/day increments. For those studies that did not
use 1000 steps per day as the base unit of analysis, we
calculated standardized risk reduction scores per 1000
steps per day. For example, if the outcome measure
reported was a hazard ratio with a unit of analysis was
2000 steps per day, the standardized risk reduction score
was calculated as the square root of the hazard ratio and
then converted to a percent risk reduction.
Fig. 1 Article screening process
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Assessment of study quality
KH and EH developed a quality assessment tool based
on the STROBE (Strengthening the Reporting of Observa-
tional studies in Epidemiology) Statement [13] and quality
assessment tool developed by Fuzeki and colleagues [14].
For each study, information on study quality was extracted
by two authors (KH and EH); differences in this assess-
ment were discussed until consensus was reached. Study
quality was determined by answers to the questions listed
in Supplementary Table 1. Briefly, study quality criteria in-
cluded assessment of study purpose, participant selection,
measurement, reporting, statistical methods, and study
limitations. Items were coded as ‘yes/present’ (1) or ‘no/
unclear/not reported’ (0). Studies scoring 8–11 were clas-
sified as high quality, those scoring 5–7 points were classi-
fied as moderate quality, and those scoring below 5 points
were classified as low quality (max score = 11) [14].
Results
Characteristics of the included studies
Seventeen studies from 13 different cohorts were in-
cluded in the systematic review; five studies assessed all-
cause mortality [15–19], four assessed cardiovascular
events [20–23], and eight assessed dysglycemia [24–31].
Follow-up measurements of health outcomes ranged
from three months [25] to 10 years [15, 19]. Sample sizes
ranged from 47 [28] to 16,741 [18], with samples com-
prised of 46.9% female participants on average. Mean
age ranged from 49.7 [27] to 78.9 [20] years; the average
baseline median number of daily step counts across
studies was approximately 6000 (range 2681 [20] to 10,
969 [24]). The studies were geographically diverse with
participants from over 40 countries; these included
Australia, the United States, the United Kingdom, South
Africa, China, and Japan. Two studies of Australian
adults in the AusDiab cohort reported nearly twice the
number of daily steps at baseline compared to other
samples (approximately 10,600 compared to approxi-
mately 5500), which may be partially due to population-
level differences in physical activity behavior across
countries. A full description of the included studies can
be found in Table 1.
The methods used to measure daily step counts in the
17 studies are described in Table 2. Eleven studies mea-
sured steps with pedometers [15, 19, 21, 23, 24, 26–31]
and six with accelerometers [16–18, 20, 22, 25]. Seven
studies [16–19, 21, 22, 26] measured daily step counts
only at baseline; ten studies [15, 20, 23–25, 27–31] in-
cluded at least one repeated measure of step counts and
subsequent health events. All studies used devices placed
at the waist or hip (data not shown). Ten studies mea-
sured steps for seven consecutive days [16–23, 26, 30],
two studies measured for at least 3 months [25, 31], and
five studies measured for durations less than 7 days
[15, 24, 27–29]. Among studies using accelerometers,
all but one [25] required at least 10 h per day of wear
time, though the number of days required for study
inclusion ranged from three [17, 20, 22] to five [16].
Two studies [23, 26], both from the NAVIGATOR
trial, used multiple imputation to address missing pedom-
eter data from the seven-day monitoring period. All other
studies excluded respondents with insufficient daily step
count data (range as percent of analytic sample: < 1–43%).
The analytic methods from all included studies are de-
scribed in Supplementary Table 2. The covariate mea-
sures in each study varied considerably; however, age,
sex, BMI and/or waist circumference, and smoking sta-
tus were the most commonly included covariate mea-
sures across all studies (Supplementary Table 2). Six
studies reported sensitivity analyses excluding the first
1–3 year(s) of follow-up [15, 17–19, 22, 23]. Five studies
assessed for significant differences in the association be-
tween daily step counts and outcomes by selected clin-
ical, behavioral, and/or demographic characteristics [15,
20, 23, 24, 26]. Thirteen studies [15–24, 26, 27, 31] ana-
lyzed total daily step counts as a continuous variable;
seven analyzed daily steps across quantiles [15–19, 22,
25]. Supplementary Table 3 shows the quality criteria
scores of each study. Ten studies were of high quality
[16–19, 21–24, 26, 30] and seven studies were of moder-
ate quality [15, 20, 25, 27–29, 31].
Daily step counts and all-cause mortality
Among the five studies assessing all-cause mortality,
three studies of high quality [16, 18, 19] and two studies
[15, 17] of moderate quality reported significant associa-
tions between greater daily step counts at baseline (con-
tinuous) and less risk of all-cause mortality. All but one
study [19] reported significant evidence of a linear rela-
tionship between steps per day and all-cause mortality
risk (Table 3). Follow-up time across studies ranged
from 4 years [16, 18] to 10 years [15, 19], and sample
sizes ranged from 201 [16] to 16,741 [18] participants. In
addition to analyzing daily step counts as a continuous
variable, all five studies analyzed daily step counts by
quantiles (Fig. 2). Each study reported significantly less
risk of all-cause mortality among those in the greatest
step count group compared to those in the least step
count group. The average daily step counts for each
quantile in Fig. 2 was plotted using quantile medians.
One study compared the observed-to-expected mortality
ratio across quantiles of average daily step counts [15],
and four used adjusted hazard regression to compare
risk of all-cause mortality in the lowest quantile of aver-
age daily step counts to all other quantiles [16–19].
Table 3 summarizes the findings of all-cause mortality
studies. Based on an assumed linear association between
daily step counts and mortality, for each study, reporting
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of the exposure of daily step counts was standardized
to 1000 steps per day difference at the baseline as-
sessment. The estimates for mortality are based on
21,118 participants and 103,723 person-years. The
standardized risk reduction across the five studies per
each 1000 daily steps increase at baseline ranged from
6% [15] to 36% [16].
One study explored prospective change in daily step
counts and subsequent all-cause mortality risk among a
subsample of participants [15]. The authors reported
that any increase in daily step count over time, com-
pared to no change or decrease over time, was associated
with reduced mortality (AHR, 0.38, 95% CI, 0.21–0.70,
P = 0.002). This finding was difficult to interpret, how-
ever, because the reference group included those with ei-
ther no change or reduced step counts. In addition, the
authors noted more deaths were observed than expected
in the reference group. Four studies [15, 17–19] con-
ducted sensitivity analyses by removing deaths in the
first 1–3 years of follow-up and reported no meaningful
differences; of studies that tested for interactions, no
significant interaction effects between steps and sex
[15, 19], age [15, 17], or health conditions (e.g.,
weight status, chronic disease) and behaviors (e.g., alcohol
use, diet) were reported (data not shown) [15, 17, 18].
Daily step counts and CVD morbidity or mortality
Among the four studies assessing CVD morbidity or
mortality, three studies of high quality [21–23] and one
study of moderate quality [20] reported significant asso-
ciations between greater daily step counts at baseline
(continuous) and lower risk of CVD. These prospective
studies reported CVD outcomes including calculated
cardio-metabolic risk score [22], composite CVD mor-
bidity or mortality — which included myocardial infarc-
tion, stroke, or heart failure [23], and two different
composites of CVD incidence and mortality [21, 24].
The follow-up time across all four studies ranged from
6months [21] to 6 years [22]. Sample size ranged from
1181 (a prospective cohort of men) [22] to 9018 [24]
participants.
Fig. 2 Associations of quantile mediansa of baseline daily step counts and all-cause mortality across included studies. Abbreviations: O:E, ratio of
observed and expected deaths, AHR, adjusted hazard ratio; CI, confidence interval; Note: Error bars represent the lower and upper bounds of the
95% confidence interval. aQuantile medians of daily step counts at baseline were not reported by Jefferis and colleagues [17]. Therefore, the
midpoints of the quantile ranges of daily step counts at baseline were plotted instead. bDwyer, 2015 reported the distribution of obeserved and
expected deaths (confidence intervals not reported) by quantiles of daily step counts at baseline. Shading on the figure indicates the distinction
in measure of association from the other four studies, all of which assessed the associations of quantiles of daily step counts at baseline and the
adjusted hazard ratio for all-cause mortality
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All four studies reported significant evidence of a lin-
ear relationship between greater steps per day and lower
risk of CVD morbidity or mortality. The reported risk
reduction in CVD varied based on unit of difference in
daily step counts. One study assessed quartiles of base-
line daily step counts and reported significantly lower
risk of CVD among those in the greater daily step count
groups compared to those in the least step counts group
[22]. Table 3 summarizes the findings of three studies
[20, 22, 23] whose analytic methods and results were
comparable. The other study identified in this review
was not included in this table because the health out-
come (composite cardio-metabolic risk score) was not
consistent with the other studies [21]. Based on an as-
sumed linear association between daily step counts and
CVD morbidity and mortality, for each study, reporting
of the exposure of daily step counts was standardized to
1000 steps per day difference at the baseline assessment.
The estimates for CVD are based on 11,789 participants
and 54,175 person-years. The standardized risk reduc-
tion in CVD events across three studies per each 1000
daily steps increase at baseline ranged from 5% [23] to
21% [20].
One study explored change in daily steps and subse-
quent CVD across repeated measurement periods [23].
Two studies conducted sensitivity analyses of previous
CVD history and reported it had no effect on the associ-
ation between daily step counts and incident CVD [20,
23]. Only one study conducted interaction analyses
(Supplementary Table 2), and found no significant ef-
fects of age, sex, or baseline daily step counts [23].
Daily step counts and dysglycemia
Eight prospective studies [24–30] examined the relation-
ship between daily step counts and dysglycemia; three
studies were high quality [24, 26, 30] and five were mod-
erate quality [25, 27–29, 31]. Four studies examined as-
sociations in the context of a lifestyle intervention for
adults with, or at high risk of type 2 diabetes mellitus
[25, 28, 29, 31]; two were conducted in the AusDiab pro-
spective cohort [24, 27]; and two reported on the NAVI-
GATOR trial [26, 30]. The four lifestyle intervention
studies [25, 28, 29, 31] were small (< 100 participants)
and had short follow-up times (≤1 year) compared to the
AusDiab and NAVIGATOR studies. Three of the inter-
vention trials targeted increased walking or daily steps
[28, 29, 31], and one targeted increased physical activity
[25]. All four lifestyle intervention studies were treated
as cohorts and the associations between daily step
counts and the outcomes were assessed across the whole
sample, regardless of study arm. These prospective stud-
ies reported on a number of dysglycemia outcomes in-
cluding blood glucose levels and HbA1c, insulin
resistance, 2-h glucose, insulin sensitivity (e.g., HOMA-
IR), and incident dysglycemia or type 2 diabetes.
Results across the longitudinal studies were mixed.
Two studies examined the association between daily step
counts and insulin sensitivity (assessed by HOMA-IR):
one small study reported no association [25] and one
large study reported a weak inverse association [24]. Six
studies examined the association between daily step
counts and fasting glucose or HbA1c: four reported no
significant associations [25, 29–31], and two reported
significant inverse associations [27, 28]. Two small stud-
ies with short follow-up examined daily step counts and
fasting insulin; both reported no association [25, 28].
Three studies examined the association between daily
step counts and 2-h glucose: one reported no association
[25] and two reported weak inverse associations [28, 30].
Two larger studies with 5-year follow-up examined the
association between daily step counts and incident dys-
glycemia or type 2 diabetes and found significantly re-
duced risk with greater daily step counts [26, 27]. Four
studies tested interactions with confounding variables
[24, 26, 27, 30] (Supplementary Table 2); they reported
no significant effects of sex [24, 26, 27], age [27], or
health measures [24, 27, 30] (e.g., insulin sensitivity,
smoking status, glucose tolerance, cardiovascular
conditions).
Table 3 summarizes the findings of two studies [26,
27] whose analytic methods and results were compar-
able. The six other studies [24, 25, 28–31] identified in
this review were not included in this table because no
point estimate for risk reduction was reported for dys-
glycemia outcomes. Four studies tested linear models
and all reported significant evidence of linearity for the
relationship between daily step counts and dysglycemia
outcomes [24, 26, 27, 30]. Based on an assumed linear
association between daily step counts and dysglycemia,
for each study, reporting of the exposure of daily step
counts was standardized to 1000 steps per day difference
at the baseline assessment. Two studies had standardized
risk reduction estimates for dysglycemia outcomes: 2%
[26] for incident diabetes among individuals with im-
paired glucose tolerance, and 13% [27] for incident dys-
glycemia among individuals with normal glucose
tolerance.
Discussion
This systematic review provides evidence of the benefit
of increasing steps per day for health: taking more steps
per day was associated with lower risk of all-cause mor-
tality, and lower risk of CVD morbidity or mortality.
Even at low levels of activity, taking an additional 1000
steps per day was associated with lower risk of all-cause
mortality, and lower risk of CVD morbidity or mortality.
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These associations appear to hold across age, gender,
and weight status.
This systematic review of 17 prospective studies extends
the findings of the 2018 Physical Activity Guidelines Ad-
visory Committee Report, which was limited to seven pro-
spective studies, and provides a current summary of the
prospective association between daily steps and mortality
and cardiometabolic biomarkers [6, 7]. Our results are in
agreement with previous studies which have reported that
increases in walking (primarily based on self-report) are
associated with lower risk of all-cause mortality, and CVD
mortality and risk factors in adults [3, 32, 33].
We identified three new longitudinal studies of daily
steps and all-cause mortality, all with large numbers, that
were not included in the previous review [6]. For each
1000 step per day increase at baseline, we report a range
of possible risk reductions in all-cause mortality (6–36%)
over 4–10 years. This is a considerable expansion from the
6–7% risk reduction reported in a previous review with
fewer studies [6]. Importantly, reduced risk of mortality
was observed even at low levels of daily steps, below the
commonly ascribed 10,000 steps per day threshold (Fig. 2).
There were too few studies to test the shape of the dose-
response relationship, though our results suggest less
mortality risk in adults with the greatest compared to the
least daily step counts, a suggestion of “more is better”
with respect to mortality risk. We identified two new lon-
gitudinal studies of daily steps and CVD morbidity or
mortality that were not included in a previous review [6].
For each 1000 step per day increase at baseline, we report
a range of possible risk reductions in CVD morbidity and
mortality (5–21%) over 2–5 years. This is a considerable
expansion from the 5% risk reduction reported in a previ-
ous review with fewer studies [6].
In contrast to our findings for all-cause mortality and
CVD mortality and morbidity, our study could not de-
finitively characterize the association between dysglyce-
mia and diabetes using the eight studies identified.
These inconsistent findings may be because of the het-
erogeneity of glycemia-related biomarker outcomes, ana-
lytic approaches, and sample characteristics. However,
results from four large cohort studies with longer
follow-up time do suggest a beneficial effect of increas-
ing daily steps on incident diabetes (in adults with and
without impaired glucose tolerance), fasting glucose and
insulin sensitivity (in adults without impaired glucose
tolerance), and 2-h glucose (in adults with impaired glu-
cose tolerance) [24, 26, 27, 30]. The findings from these
four cohort studies are consistent with the findings of
other systematic reviews that find that diabetes risk de-
clines with increased levels of overall physical activity
[34, 35]. The 2018 Physical Activity Guidelines Advisory
Committee also concluded that there was limited evi-
dence of an association between daily step counts and
reduced risk of type 2 diabetes incidence [7, 26]; and we
did not identify any new data in the present report. Add-
itional evidence from longitudinal studies is needed to
determine the association between daily steps and dys-
glycemia outcomes and to provide dose-response data.
Our findings appear to be robust to threats from con-
founding or bias. For all health outcomes, the effect of
daily step counts was robust to adjustment for sociode-
mographic (e.g., age, sex), individual (e.g., weight status,
disease history), and lifestyle characteristics (e.g., smok-
ing, alcohol use). The generalizability of these conclu-
sions is also supported by the representation of men and
women, healthy and at-risk populations, and diverse
geographical areas in this systematic review. However,
only five studies (representing just two unique prospect-
ive studies) reported the racial/ethnic characteristics of
the sample [20, 21, 23, 26, 30] and just three studies re-
ported the socioeconomic (e.g., education, social class,
income) characteristics [16, 20, 22]. Based on the avail-
able information, it appears the majority of participants
in the studies included in this review were white adults,
from developed countries, and of higher socioeconomic
status. As a result, it is not clear how generalizable our
results are to racial/ethnic minorities or low- and
middle-income persons or settings.
Several methodological issues in the individual studies
could have affected the findings in our review. First, we
noted large disparities in the number of participants in-
cluded in the analyses of daily steps counts and health
outcomes compared to 1) the overall cohort sample sizes
and 2) the number of adults with steps data at baseline.
The issue of missing follow-up data among those partici-
pants with baseline exposure data also went largely un-
addressed in these prospective studies (only 18%
reported methods for dealing with missing data; Supple-
mentary Table 3, item #6). Both of these issues could
have biased associations or limited the generalizability of
study results. Second, although the studies included in
the review were all moderate-to-high quality, there was
considerable heterogeneity in sample size and outcome
follow-up time. Only eight studies, representing four
unique prospective cohorts, reported on sample sizes
≥1000 participants and follow-up time period ≥4 years;
the remaining studies were substantially smaller and/or
had follow-up time of only 3 months to 2 years. This
field would benefit from larger studies of longer duration
(> 5 years) that provide robust estimates of the associ-
ation of daily step counts with health outcomes. Finally,
the cardiovascular and dysglycemia outcome measures
also varied considerably across studies, with several
using composite measures of differing cardiovascular
events and dysglycemia markers ranging from insulin
sensitivity to incident diabetes; this further complicated
comparisons across studies.
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We also identified methodologic limitations specific-
ally pertaining to exposure assessment of steps in the in-
dividual studies that warrant further discussion in the
context of future research. First, we noted that different
wearable devices were used to assess steps. Pedometers,
while extremely useful for epidemiologic assessment,
often lack the ability to store data in memory on the de-
vice, requiring participants to complete step logs [36].
Newer devices, such as accelerometers, have demon-
strated excellent reliability and validity for walking,
though this depends on where they are placed (usually
waist-worn) and the model of the accelerometer [36, 37].
These devices often rely on proprietary algorithms to es-
timate step counts, making data interpretation challen-
ging. The increasing popularity of wrist-worn consumer
devices and smartphones for monitoring step counts
[38] is sure to add another element of measurement
variability and may introduce issues when translating re-
search findings into public health recommendations.
Second, although recommended study protocols for
length and duration of accelerometer wear exist, our review
found that over one-third did not carry out exposure meas-
urement using these conventional methods [39] (Supple-
mentary Table 3, item #4). These protocols include ≥4 days
of monitoring (pedometer and accelerometer studies), valid
wear time defined as ≥10 h/day (accelerometer studies
only); reporting data processing criteria (accelerometer
studies only). Despite these inconsistencies, we report that
as little as 2–7 days of assessment across studies was pre-
dictive of mortality and CVD outcomes. Standardized
methods across studies will improve comparability, and fu-
ture efforts to ensure adequate measurement and analysis
of step count data will greatly improve this field of research.
As activity monitoring devices are being integrated success-
fully into numerous large-scale prospective trials, repeated
measures of step count data and subsequent health events
will be available. The logistical and analytic insights from
these studies could improve standardization as well as our
understanding of the prospective relationship [40–42].
Our systematic review examined studies published
from over the past 70 years. Despite a robust search
strategy, we identified only a small number of longitu-
dinal studies assessing daily steps and health outcomes.
Many of these studies were conducted recently (past 1–
8 years), demonstrating this as a new area of research. In
addition, while 10 of the included studies included at
least one repeated measure of daily step counts, only
two studies prospectively examined the association of
change in daily step counts and subsequent risk of the
outcome [15, 23]. However, a recent study found that
stability in accelerometer measured daily step counts ap-
pears stable over 2–3 years [41]. Although originally
planned, we were not able to conduct meta-analyses of
these studies due to the lack of standardized metrics
(e.g., per 1000 steps, quantiles) and heterogeneity of
study designs and populations. The lack of detailed in-
formation (e.g., point estimate and standard error) in the
papers also precluded our ability to harmonize across
the studies. To address these needs, we urge authors to
provide detailed information in future publications on
risk factor analyses and related parameters required for
meta-analysis [43–45].
This is the largest systematic review to date of pro-
spective associations between daily step counts and im-
portant health outcomes, reporting on 17 geographically
diverse studies drawn from 12 unique cohorts. The 2018
Physical Activity Guidelines Advisory Committee identi-
fied a need for more evidence of the longitudinal associ-
ations between daily steps and risk of mortality, CVD,
and dysglycemia. This systematic review addresses this
need and identifies opportunities for additional studies
to advance the field and build the evidence base around
daily steps for health. Information on steps and health
may be used to augment current recommendations on
the amount of physical activity needed for health. Al-
though physical activity (e.g., frequency, intensity, dur-
ation) may be easy to intuit for someone who exercises
regularly, individuals who participate in activities such as
gardening, house cleaning, or walking for errands may
have difficulty determining the duration and intensity of
these activities. Among such people, using daily steps
obtained from activity trackers may be another way to
promote public health guidelines and help individuals
achieve the recommended amounts of physical activity.
Another strength of the current review is that it investi-
gates individual cardiometabolic biomarkers (e.g., insulin
sensitivity, fasting glucose, cardio-metabolic risk score)
in addition to global measures of cardiovascular and
metabolic health (e.g., type 2 diabetes, CVD).
In conclusion, there was consistent evidence from longi-
tudinal data that walking an additional 1000 steps per day
can help lower the risk of all-cause mortality, and CVD
morbidity and mortality in adults, and that health benefits
are present below 10,000 steps per day. Our review also
demonstrates a current lack of data on the relationship be-
tween step counts and subsequent health outcomes to ad-
equately inform a daily step count guideline [7, 8].
Additional evidence can come from completing new ana-
lyses of existing studies with the requisite exposure and
outcome measures reported here, or by designing new
studies that address some of the limitations noted in our
review. These studies could include using standard meth-
odologies and examine the relationship in different sub-
groups of the population. This additional evidence will
help guide meaningful volume targets that can be used for
health care, education, and behavioral interventions, and
potentially inform the development of public health guide-
lines for steps and health.
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